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Background:  CD31+/Annexin V+ microparticles (MP) are increased in patients with cardiovascular risk factors and impaired coronary endothelial 
function. We evaluated whether MPs are an independent marker for cardiovascular events in patients with stable coronary artery disease (CAD).
Methods:  The number of CD31+/Annexin V+ MP was determined by flow cytometry in 200 patients (age 66.1±10.4 years). The median follow-up 
time for MACCE-free survival was 6.1 (6.0/6.4) years. 4 patients were lost to follow-up.
Results:  A first major adverse cardiovascular and cerebral event (MACCE) occurred in 72 patients (37%). MP levels were significantly higher 
in patients with MACCE (P=0.004). The prevalence of diabetes (P=0.02) and male gender (P=0.05) were significantly related to the MP level. In 
multivariate analysis (cardiovascular risk factors, history of myocardial infarction, number of diseased vessels, medication), high MP levels were 
associated with a higher risk for cardiovascular death (HR 3.6, 95%-CI 1.0-13.0; P=0.05), the need for revascularization (HR 2.3, 95%-CI 1.3-4.0; 
P=0.006), and the occurrence of a first MACCE (HR 2.5, 95%-CI 1.5-4.1; P<0.001). Inclusion of the MP level into a classical risk factor model 
substantially increased c statistics from 0.637 (95% CI: 0.557-0.717) to 0.702 (95% CI: 0.625-0.780) (P=0.03).
Conclusions:  The level of circulating CD31+/Annexin V+ MPs is an independent predictor of cardiovascular events in CAD patients and may be 
useful for risk stratification. 
